Laurus Labs Ltd (NSE: LAURUSLABS, BSE: 540222) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,31,242 Cr, it ranks #79 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,424.00 (as of 16 Nov 2026), the share price is 2.6% below its 52-week high of ₹2,488.00 and 156.5% above its 52-week low of ₹944.90. The share price is up 146.8% over one year and up 30.9% over three months.
| Current Price | ₹2,424.00 |
|---|---|
| Market Cap | ₹1,31,242 Cr |
| NSE Symbol | LAURUSLABS |
| BSE Code | 540222 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 145.6 |
| Return on Equity | 17.74% |
| Return on Assets | 8.18% |
| 52-Week Range | ₹944.90 – ₹2,488.00 |
| 1-Year Price Change | +146.8% |
| 3-Month Price Change | +30.9% |
| Beta (1Y) | 0.51 |
| Dividend Yield | 0.10% |
| Headquarters | Hyderabad, Telangana |
| Website | www.lauruslabs.com |
| Revenue | ₹2,206 Cr |
|---|---|
| Net Profit | ₹436 Cr |
| Net Margin | 19.8% |
| EPS (Basic) | ₹8.17 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Laurus Labs Ltd reported revenue of ₹2,206 Cr in Q2 FY27, up 33.4% from ₹1,653 Cr in Q2 FY26 and up 8.9% from ₹2,026 Cr in Q1 FY27. It posted a net profit of ₹436 Cr for the quarter, against a net profit of ₹194 Cr in Q2 FY26 (up 124.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,570 Cr (Q1 FY26) to ₹2,206 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,206 Cr | ₹436 Cr | 19.8% |
| Q1 FY27 | ₹2,026 Cr | ₹362 Cr | 17.9% |
| Q4 FY26 | ₹1,812 Cr | ₹282 Cr | 15.6% |
| Q3 FY26 | ₹1,778 Cr | ₹252 Cr | 14.2% |
| Q2 FY26 | ₹1,653 Cr | ₹194 Cr | 11.8% |
| Q1 FY26 | ₹1,570 Cr | ₹162 Cr | 10.3% |
| Q4 FY25 | ₹1,720 Cr | ₹233 Cr | 13.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 27.47% of Laurus Labs Ltd's shares as of Sept 2026, against 27.59% in Sept 2025 (−0.12 percentage points). Delivery averaged 46.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
1. Manufacture of Active Pharmaceutical Ingredients, Intermediates and Formulations-This segment engages in the manufacture of active pharmaceutical ingredients, intermediates, and formulations. 2. Infosystems-This segment engages in the production and development of Internet programs, products, services, and applications. 3. Corporate-0
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Glenmark Pharmaceuticals Limited | ₹75,556 Cr | 55.1 | 14.07% | ₹4,157 Cr | +45.7% |
Listed by market capitalisation. Ratios are shown for context only.
Laurus Labs Ltd is trading at ₹2,424.00, with a market capitalisation of ₹1,31,242 Cr.
Laurus Labs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Laurus Labs Ltd has a P/E of 145.6 and a return on equity of 17.74%.
Laurus Labs Ltd is listed on the NSE under the symbol LAURUSLABS and on the BSE under the scrip code 540222.
Laurus Labs Ltd's share price is up 146.8% over one year and up 30.9% over three months. Its 52-week range is ₹944.90 to ₹2,488.00.
In Q2 FY27, Laurus Labs Ltd reported revenue of ₹2,206 Cr and net profit of ₹436 Cr, with basic EPS of ₹8.17 (consolidated, parsed from the company's exchange filing).
Laurus Labs Ltd reported revenue of ₹2,206 Cr in Q2 FY27, up 33.4% from ₹1,653 Cr in Q2 FY26 and up 8.9% from ₹2,026 Cr in Q1 FY27.
Promoters held 27.47% of Laurus Labs Ltd's shares as of Sept 2026, against 27.59% in Sept 2025 (−0.12 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.